Research Use Only - Not for human consumption. 18+ only.

KPV vs VIP

Evidence-based comparison · Updated 2026

Summary

KPV is better suited for localized gut inflammation, particularly conditions like IBD and IBS, while VIP is a broader neuroimmune modulator used in systemic inflammatory conditions including CIRS and autoimmune disorders. Choose KPV for targeted intestinal anti-inflammatory support and VIP when systemic immune dysregulation, neuroprotection, or CIRS is the primary concern. VIP carries a stronger evidence grade (B vs C), making it the more clinically supported option overall.

Side-by-Side Comparison

KPVVIP
EvidenceCGrade CPrimarily animal or in-vitro studies; limited human dataBGrade BSmaller human trials, observational studies, or approved in 30+ countries
RegulatoryResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits
  • +Strong anti-inflammatory effects
  • +Gut healing properties
  • +Reduces inflammatory cytokines
  • +May help IBD and IBS
  • +Wound healing support
  • +Modulates immune system
  • +Reduces inflammation
  • +Treats CIRS and mold illness
  • +Neuroprotective effects
  • +Improves pulmonary function
Dosage500-1000 mcg mcg — 1-2x daily50 mcg mcg — 4x daily
RouteSubcutaneous, OralIntranasal
CategoryImmune & Inflammatory ModulationImmune & Inflammatory Modulation

Full research page

KPV →

Full research page

VIP →

Which Should You Choose?

KPV acts locally through melanocortin receptors with a focus on gut mucosal inflammation, while VIP operates across the neuroimmune axis via VPAC1 and VPAC2 receptors, affecting both the nervous system and systemic immune response.

Choose KPV when:

  • +Primary concern is intestinal inflammation such as Crohn's disease, ulcerative colitis, or IBS with an inflammatory component
  • +Looking for a peptide with a well-defined gut-specific mechanism and a minimal systemic side effect profile
  • +Goal is localized wound healing or mucosal repair rather than broad immune modulation

Choose VIP when:

  • +Dealing with systemic inflammatory conditions such as CIRS, mold illness, or mast cell activation syndrome
  • +Neuroprotection or autonomic nervous system support is part of the research objective alongside immune modulation
  • +Stronger evidence base is a priority, as VIP holds a grade B rating compared to KPV's grade C

Stacking KPV and VIP is occasionally explored in research contexts targeting both gut-specific and systemic inflammatory pathways simultaneously, though no clinical trial data currently validates this combination.

Frequently Asked Questions

Can KPV and VIP be used together, and is there a rationale for stacking them?⌄
A theoretical rationale exists for combining KPV and VIP, since KPV targets melanocortin receptor-mediated inflammation in the gut mucosa while VIP modulates the broader neuroimmune axis. Together they could address both localized intestinal and systemic inflammatory signalling. However, no peer-reviewed studies have evaluated this stack directly, so any combined use remains speculative and confined to research settings.
How do the onset timelines of KPV and VIP differ in research models?⌄
KPV research in murine colitis models suggests measurable reductions in intestinal inflammatory markers within days of administration, reflecting its targeted local mechanism. VIP, acting systemically across the neuroimmune axis, tends to be studied over longer treatment windows in chronic conditions like CIRS, where immune recalibration occurs gradually. Direct head-to-head timeline comparisons between the two peptides are not available in published literature.
Which peptide is more appropriate if inflammation is present in both the gut and systemically?⌄
When both localized gut inflammation and systemic immune dysregulation are present, VIP may be the more pragmatic single-peptide choice given its broader receptor distribution across intestinal and systemic compartments. KPV's mechanism is more narrowly focused on mucosal and gut-associated immune cells. If research protocols allow, some investigators have explored addressing both targets simultaneously through a stacked approach, though clinical evidence for this strategy is lacking.
Does the difference in evidence grade between KPV and VIP affect how researchers approach dosing protocols?⌄
VIP's higher evidence grade (B) reflects more extensive study, and as a result there are more documented dosing frameworks in the research literature, particularly for CIRS protocols developed by physicians such as Dr. Ritchie Shoemaker. KPV's grade C rating indicates that dosing parameters are derived largely from preclinical and early-phase work, meaning protocols are less standardized. Researchers working with KPV typically extrapolate from animal study data, which introduces greater uncertainty compared to VIP.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500mots c vs semaglutidedsip vs melanotan iiretatrutide vs tirzepatidecjc 1295 vs ipamorelin